ECOG-ACRIN Staff

December 20, 2022

A General Session to Remember: NCI Director Monica Bertagnolli Delivers First Public Speech, ECOG-ACRIN Honors Two Esteemed Colleagues

Some of the most memorable moments of the 10th Anniversary General Session featured three individuals who have been key participants and collaborators in ECOG-ACRIN’s research over the years
December 20, 2022

Trial Spotlight: Robert Ferris and Christine Chung on the EA3132 Trial for Patients with Head and Neck Cancer

This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck